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Abstract: This study investigates for the first time the crosstalk between stromal fibroblasts and
cancer stem cell (CSC) biology in head and neck squamous cell carcinomas (HNSCC), with the
ultimate goal of identifying effective therapeutic targets. The effects of conditioned media from
cancer-associated fibroblasts (CAFs) and normal fibroblasts (NFs) on the CSC phenotype were
assessed by combining functional and expression analyses in HNSCC-derived cell lines. Further
characterization of CAFs and NFs secretomes by mass spectrometry was followed by pharmacologic
target inhibition. We demonstrate that factors secreted by CAFs but not NFs, in the absence of
serum/supplements, robustly increased anchorage-independent growth, tumorsphere formation, and
CSC-marker expression. Modulators of epidermal growth factor receptor (EGFR), insulin-like growth
factor receptor (IGFR), and platelet-derived growth factor receptor (PDGFR) activity were identified
as paracrine cytokines/factors differentially secreted between CAFs and NFs, in a mass spectrometry
analysis. Furthermore, pharmacologic inhibition of EGFR, IGFR, and PDGFR significantly reduced
CAF-induced tumorsphere formation and anchorage-independent growth suggesting a role of these
receptor tyrosine kinases in sustaining the CSC phenotype. These findings provide novel insights
into tumor stroma–CSC communication, and potential therapeutic targets to effectively block the
CAF-enhanced CSC niche signaling circuit.
Keywords: head and neck squamous cell carcinoma; cancer-associated fibroblasts; cancer stem cells;
tumor microenvironment; secretome; therapeutic target
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1. Introduction
Mounting evidence indicates that tumors are highly complex heterogeneous structures in
which growth is supported not only by the cancer cells themselves, but also the surrounding
microenvironment. Since cancer must be considered as a systemic disease, an in-depth understanding
of tumor progression requires knowledge of the role of both tumor cells and infiltrating stroma, as well
as how these distinct cell types interact to drive tumor biology. The tumor stroma is constituted by
various types of stromal cells and the extracellular matrix (ECM), collectively denominated as tumor
microenvironment (TME) [1].
Fibroblasts are a major component within the TME, and in particular, cancer-associated fibroblasts
(CAFs) play a key role in tumorigenesis, as they significantly contribute to important hallmarks
necessary for cancer progression, such as sustained growth, invasion, inflammation, angiogenesis,
metastasis, and therapeutic resistance [2,3]. It is well established that tumor cells can stimulate stromal
cells to release paracrine factors that facilitate cancer growth and dissemination. Specifically, CAFs
emerge as critical players in this process, stimulating cancer progression toward aggressive phenotypes
through cell–cell communication with cancer cells or other stromal cells, remodeling the ECM and
releasing a plethora of growth factors, chemokines, cytokines, and matrix metalloproteinases (MMPs)
in the TME [4]. Accordingly, the presence of CAFs has been widely associated with poor prognosis in
numerous tumor types, including among others, gastric, colorectal, breast, and prostate cancers [5,6].
Tumors are hierarchically organized with different cancer cell subpopulations, where cancer
stem cells (CSCs) are essential for tumor initiation, treatment resistance, relapse, and metastasis [7,8].
CSCs are regulated by, and in turn regulate, cells within the TME. Recent findings have shown
the plasticity and phenotype switching of the different cancer cell subpopulations [9–11]. Thus,
malignant epithelial cells may dedifferentiate, and thereby enter back into the stem cell pool. Therefore,
therapies aimed at targeting CSCs within the tumor will not be curative if the CSCs pool can be
continuously regenerated from plastic non-CSCs capable of dedifferentiating and reentering the CSC
state. There are strong indications that CAFs may regulate CSCs in various ways: (i) acting directly
on the CSCs subpopulation to promote their self-renewal; (ii) re-inducing a stem cell phenotype in
more differentiated tumor cells (reprogramming); or (iii) activating autocrine signaling loops in tumor
cells that maintain them into a stem cell-like state [12]. Consequently, the identification of molecules
responsible for the conversion of non-CSCs into CSCs is indispensable to select the most appropriate
drugs, or combinations of them, to efficiently eliminate CSCs populations, and subsequently reduce
the risk of metastasis outgrowth and tumor relapse.
Previous functional studies have demonstrated that secreted proteins, acting as paracrine factors,
provide an important bidirectional communication system between cancer cells and the surrounding
fibroblasts. Hence, the secretome from both tumor and stromal cells may constitute a rich reservoir of
potential biomarkers and/or new therapeutic targets [13,14]. Likewise, as secreted proteins, they have
the potential of being released into blood circulation or saliva, thus increasing the possibility of their
detection in patient-derived body fluids.
Therefore, a deeper understanding of the molecules involved in the interaction between CSCs
and CAFs is fundamental to find novel targets to block effectively the communication between
them, and ultimately prevent their cooperative roles in promoting tumor progression. This study
investigated for the first time the crosstalk between stromal fibroblasts and CSC in the context of head
and neck squamous cell carcinomas (HNSCC). Using mass spectrometry (MS) we identified various
CAF-secreted molecules potentially responsible for sustaining CSC properties in HNSCC-derived cell
lines. In addition, pharmacological targeting of signaling pathways related to the identified factors
effectively blocked CAF-induced CSC phenotype, thus suggesting their potential as novel therapeutic
targets to overcome CSC-mediated disease progression and resistance to therapy.
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2. Results
2.1. Fibroblast-Secreted Factors Sustain Cancer Stem Properties of HNSCC Cells
Cancer stem cells (CSCs) play critical roles in tumor initiation, progression, recurrence, and
treatment resistance. However, the crosstalk between CAFs and CSCs in the context of HNSCC has not
yet been explored. This prompted us to investigate the effect of CM from CAFs or NFs on cancer stem
properties in HNSCC cells, such as tumorosphere formation, anchorage-independent growth, and
expression of CSC markers. We first assayed the ability of fibroblast-CM to promote the formation of
clonal spheres (tumorspheres) in non-adherent and serum-free culture conditions (Figure 1). We found
that both FaDu and SCC38 cells were able to form orospheres when grown in NF-CM, and much more
efficiently in CAF-CM, showing bigger size spheres similar to those formed in the presence of stem
supplemented medium, used as a positive control by its high efficiency to induce orosphere formation.
As expected, HNSCC cells were unable to form orospheres in non-supplemented medium, which
served as a negative control.
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Figure 1. Effect of fibroblast-CM (conditioned media) on the tumorsphere formation capacity of head
and neck squamous cell carcinomas (HNSCC) cells. Representative images of orospheres formed
by (A) FaDu and (B) SCC38 cells in non-supplemented medium, supplemented medium, and CM
from normal fibroblasts (NFs) or cancer-associated fibroblasts (CAFs). Bar chart showing the average
diameter of spheroids formed by (C) FaDu and (D) SCC38 cells in the previous conditions. All data
were expressed as the mean ± SD of at least three independent experiments performed. Scale bar:
500 µm. *** p < 0.001 and ** p < 0.01 by Holm-Sidak’s multiple comparisons test.
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Consistently, we also found that CAF-CM, and to a less extent NF-CM, significantly increased
anchorage-independent growth in both FaDu and SCC38 cells, compared to non-supplemented
medium (Figure 2). These results indicate that components of the CAF-CM promote CSC properties in
HNSCC cells.
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Figure 2. Effect of fibroblast-CM on anchorage-independent growth of HNSCC cells. (A) FaDu and
(B) SCC38 cells were seeded in plates coated with Poly(2-hydroxyethyl methacrylate) (polyHEMA)
and grown in non-su plemented medium, CM from NFs, CM from CAFs, or su plemented medium.
Cell proliferation was estimated by tetrazolium-based MTS assay after 4 days. Data were normalized
to the absorbance at day 0 and relative to control (non-supplemented) cells. All data were expressed as
the mean ± SD of at least three independent experi ents perfor ed in quadruplicate. *** p < 0.001,
** p < 0.01 and * p < 0.05 by Holm-Sidak’s multiple comparisons test.
2.2. Fibroblast-Secreted Factors Induced the Expression of Stemness-Related Genes in HNSCC Cells
The results above suggest that CAF-CM may be inducing stem properties in HNSCC cells.
To verify this observation and to gain further insight into the mechanisms by which stromal fibroblasts
may promote CSC features in HNSCC cells, we analyzed the expression of several CSC markers and
other genes with well-known functions in pluripotency, self-renewal, and signal transduction in CSCs.
Thus, we performed RT-qPCR in orospheres formed by FaDu and SCC38 cells treated with
CAF-CM or supplemented medium and gene expression was compared to that of adherent
control cultures. Overall, we observed an increase in the mRNA levels of several CSC-related
genes in orospheres formed in CAF-CM and supplemented medium, compared to adherent cells
(Figure 3). Thus, CAF-CM potently and consistently increased the mRNA levels of ALDH1, NANOG,
SOX2, and OCT4. There were some noticeable differences between supplemented medium and
fibroblast-CM-formed orospheres, depending on the gene and also the HNSCC-derived cell line.
ALDH1 expression levels were highly induced in orospheres formed in supplemented medium in
FaDu cells, whereas mRNA levels of NANOG, ABCG2, CD44, CD133, and Nestin were more robustly
induced in CAF-CM-formed orospheres in HNSCC cells. These results suggest that CAF-CM and
supplemented medium regulate stemness by activating different signal transduction programs in
HNSCC cells to sustain the CSC-phenotype.
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2.3. Identification of Fibroblast-Secreted Proteins by Mass Spectrometry
We next performed a Mass Spec analysis in NFs and CAFs to identify the repertoire of
CAF-secreted proteins that may be responsible for sustaining cancer stem properties in HNSCC
cells. Comparison of protein expression levels in the secretomes was conducted using three different
biological replicates for each cell line.
Secretome analysis provided valuable information on the proteins differentially secreted by
CAFs compared to NFs (Figure 4). We identified 41 extracellular proteins differentially secreted
by CAFs versus NFs (fold change > 2 or <−2) (Table 1). Among the most highly up-regulated
proteins, we selected for further study Carboxypeptidase E (CBPE), which has been implicated in
cell proliferation and survival in other cancer types [15,16], as well as platelet-derived growth factor
D (PDGFD), epidermal growth factor (EGF)-containing fibulin-like extracellular matrix protein-1
(FBLN3), insulin-like growth factor binding protein-5 (IBP5) and insulin-like growth factor binding
protein-7 (IBP7), respectively associated to growth factor-signaling pathways through PDGF, EGF, and
insulin-like growth (IGF) receptors [17–19].
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Table 1. Proteins differentially secreted in CAFs versus NFs.
UNIPROT_ID e a e Fold ChangeCAFs p-Value
HNRPL_HUMAN heteroge l i onucleoprotein L(HNRNPL) 6.92 0.020
CBPE_HUMAN tidase E(CPE) 6.76 0.020
CO7_HUMAN l ent C7(C7) 6.08 0.046
PDGFD_HUMAN plat l r th factor D(PDGFD) 5.87 >0.001
FBLN3_HUMAN EGF containing fibulin like extracellul r matrix protein1(EFEMP1) 4.50 0.031
IBP5_HUMAN insulin like gro th factor binding protein 5(IGFBP5) 3.89 0.015
DDAH1_HUMAN dimethylarginine dimethylaminohydrolase 1(DDAH1) 3.38 0.010
PGM1_HUMAN phosphoglucomutase 1(PGM1) 3.24 0.001
GREM1_HUMAN gremlin 1, DAN family BMP antagonist(GREM1) 3.09 0.010
IF4A1_HUMAN eukaryotic translation initiation factor 4A1(EIF4A1) 2.65 0.047
RS18_HUMAN ribosomal protein S18(RPS18) 2.40 0.036
TCPQ_HUMAN chaperonin containing TCP1 subunit 8(CCT8) 2.25 0.039
IBP7_HUMAN insulin like growth factor binding protein 7(IGFBP7) 2.06 0.037
TCPD_HUMAN chaperonin containing TCP1 subunit 4(CCT4) −2.07 >0.001
MARCS_HUMAN myristoylated alanine rich protein kinase Csubstrate(MARCKS) −2.22 0.042
ANXA2_HUMAN annexin A2(ANXA2) −2.24 0.018
PEDF_HUMAN serpin family F member 1(SERPINF1) −2.27 0.003
MM 3_HUMAN matrix etallopeptidase 3(MMP3) −2.29 0.002
PSA5_HUMAN proteaso subunit alpha 5(PSMA5) −2.31 0.037
CALR_HUMAN calreticul n(CALR) −2.32 0.011
BASP1_HUMAN brain abundant membrane attached signal protein1(BASP1) −2.39 0.020
VASN_HUMAN vasorin(VASN) −2.45 0.034
LUM_HUMAN lumican(LUM) −2.56 0.001
CFAD_HUMAN comple ent factor D(CFD) −2.62 0.002
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Table 1. Cont.
UNIPROT_ID Gene Name Fold ChangeCAFs p-Value
LA_HUMAN Sjogren syndrome antigen B(SSB) −2.66 0.007
UB2V1_HUMAN TMEM189-UBE2V1 readthrough(TMEM189-UBE2V1) −2.76 0.048
PSG7_HUMAN pregnancy specific beta-1-glycoprotein 7(gene/pseudogene)(PSG7) −3.28 0.003
PTGDS_HUMAN prostaglandin D2 synthase(PTGDS) −3.38 0.019
FBLN2_HUMAN fibulin 2(FBLN2) −3.40 0.012
AN32B_HUMAN acidic nuclear phosphoprotein 32 family memberB(ANP32B) −3.40 0.044
ENPP2_HUMAN ectonucleotide pyrophosphatase/phosphodiesterase2(ENPP2) −3.42 0.003
MASP1_HUMAN mannan binding lectin serine peptidase 1(MASP1) −3.58 0.007
EMIL2_HUMAN elastin microfibril interfacer 2(EMILIN2) −3.68 >0.001
CSPG4_HUMAN chondroitin sulfate proteoglycan 4(CSPG4) −4.29 0.010
APOE_HUMAN apolipoprotein E(APOE) −4.45 0.003
TENA_HUMAN tenascin C(TNC) −4.68 0.001
PDIA6_HUMAN protein disulfide isomerase family A member 6(PDIA6) −4.93 0.028
A2GL_HUMAN leucine rich alpha-2-glycoprotein 1(LRG1) −5.24 0.006
RAB2A_HUMAN RAB2A, member RAS oncogene family(RAB2A) −6.09 0.002
RL15_HUMAN ribosomal protein L15(RPL15) −6.99 0.037
PSG4_HUMAN pregnancy specific beta-1-glycoprotein 4(PSG4) −8.01 0.015
Up-regulated proteins are shown in red and down-regulated proteins in blue.
2.4. Targeting EGFR, IGFR, and PDGFR Signaling Effectively Inhibited CAF-Promoted Stemness in
HNSCC Cells
We hypothesized that the CAF-secreted proteins CBPE, PDFGD, FBLN3, IBP5, and IBP7 may
enhance CSC properties in HNSCC cells through the activation of signaling pathways involving
the activity of CBPE or receptors for EGF, IGF, and PDGF. In order to support this hypothesis,
we assessed the ability of CAF-CM to induce anchorage-independent growth in the presence of
specific pharmacologic inhibitors, as these are conveniently available as research tools. We used
drugs whose modes of action involve both receptor blockage (Gefitinib for EGFR, OSI-906 for IGFR,
and CP-673451 for PDFGR) and protein blockage (GEMSA for CBPE) [16–19]. In addition, we also
include the mithramycin analog EC-8042, since it has been recently described as a potent inhibitor of
stemness-related genes and CSCs viability in other cancers [20].
Results showed that GEMSA, Gefitinib, OSI-906, and CP-673451 reduced anchorage-independent
growth in a dose-dependent manner in both FaDu and SCC38 cells grown in CAF-CM (Figure 5).
However, cells grown in supplemented-medium were clearly less sensitive to these drugs, with only
high doses having cytotoxic effects. EC-8042 was an effective blocker of anchorage-independent
growth in both FaDu and SCC38 cells grown in either CAF-CM or supplemented-medium.
We next evaluated the effect of these compounds on orosphere formation. Our previous results
(Figure 5) provided us with information on the most appropriate concentration of compounds to be
used for these experiments. Thus, we found that Gefitinib (1 µM), OSI-906 (10 µM), CP-673451 (5
µM), and EC-8042 (0.01 µM) effectively prevented tumorsphere-forming capability of FaDu cells in
either CAF-CM or supplemented medium (Figure 6). In contrast, 10 µM GEMSA did not significantly
inhibit orosphere formation in CAF-CM, whilst increased orosphere formation in supplemented
medium. Together, these results suggest that modulators of EGFR, PDGF and IGFR activity and also
the mithramycin analog EC-8042 have the potential to inhibit stemness-related properties in HNSCC
cells, consequently emerging as potential therapeutic targets to effectively block the CAF-enhanced
CSC niche signaling circuit.
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4 days. Data were normalized to the absorbance at day 0 and relative to control (vehicle-treated) cells. 
All data were expressed as the mean ± SD of at least three independent experiments performed in 
quadruplicate. * p < 0.05, ** p < 0.01 and *** p < 0.001 by Student’s t-test. 
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3. Discussion
Recent increasing evidence has suggested that the TME is an integral and inseparable part of
malignant transformation [21,22], as it plays a significant role during tumor progression, enabling
primary growth, invasion, and metastatic spreading [23–25]. Hence, the study of the role of the
different TME components and strategies aimed at interfering with the crosstalk between cancer
cells and their cellular partners in the TME is of great interest, since it may provide novel promising
anti-cancer therapies with minimal chance to develop drug resistance [26].
This study provides original evidence demonstrating that CAF-secreted factors sustain and
robustly enhance stemness in HNSCC-derived cell lines, thereby increasing anchorage-independent
growth, tumorsphere formation, and expression of various CSC markers, such as NANOG, SOX2,
OCT4, ALDH1, CD133, CD44, and NOTCH1, in the absence of serum or any other supplements.
There are strong indications that CAFs regulate CSCs [12]. In this regard, Donnarumma and colleagues
observed that CAFs promoted cancer progression by enhancing stemness, Epithelial-mesenchymal
transition (EMT) phenotype, and anchorage-independent growth in breast cancer [27]. Also, CAFs
were found to secrete ADAM10-rich exosomes to promote cell motility and activate RhoA and Notch
signaling in several cancer cell lines [28]. Vermeulen et al. showed that primary colon CAFs released
HGF to induce nuclear translocation of ß-catenin in tumor cells and a stem cell-like transcription
profile [29]. In prostate cancer, tumor cells released IL-6 leading to fibroblasts activation, and in
turn, fibroblasts, through MMPs secretion, elicited an EMT phenotype in cancer cells, as well as
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enhancement of tumor growth and development of spontaneous metastases. CAF-induced EMT in
prostate carcinoma cells was accompanied by increased expression of CSC markers, and enhanced
ability to form tumorspheres and self-renewal [30].
Nevertheless, prior to this study, the crosstalk between CAFs and CSC in the context of head and
neck squamous cell carcinomas (HNSCC) had not been explored. To identify the molecules responsible
for mediating the conversion of non-CSCs into CSCs is indispensable to select the most appropriate
drugs, or combinations of them, to efficiently eliminate CSCs populations, and subsequently reduce
the risk of metastasis outgrowth and tumor relapse.
These reasons prompted us to perform an unbiased proteomic analysis using MS to identify the
proteins secreted to extracellular media by stromal fibroblasts that mediate paracrine communication.
Our secretome analysis showed that there were several differentially secreted proteins (over- or
under-expressed) in CAFs compared with NFs. Among the most promising and highly induced factors
that could be responsible for sustaining the CSC phenotype are FBLN3, IBP5, IBP7, and PDGFD.
FBLN3 is an extracellular protein that can bind to EGFR, inducing EGFR autophosphorylation
and the activation of downstream signaling pathways. Several groups have observed that EGFR is
over-expressed in a wide spectrum of tumors, including HNSCC [31,32]. EGFR overexpression results
in aggressive tumor behavior, radiation resistance, and poor prognosis [33]. EGFR activates several
downstream pathways, including Ras/Raf/MAPK/ERK, PI3K/Akt, STAT, and the PLC-γ signaling
pathways to potentiate growth and survival of tumor cells and CSCs [19].
IBP5 and IBP7, as IGF binding proteins, bind IGFs to regulate their activity by prolonging
their half-life and circulation turnover, and by controlling their binding to IGFR, either positively or
negatively, affecting the IGF signaling pathway [34]. IBPs may inhibit mitogenesis, differentiation,
survival, and other IGF-stimulated events by sequestering IGFs away from the IGFR [35,36]. Also, they
can function independently of IGF signaling pathway via interacting with proteins other than IGFs
binding their own membrane receptors [37]. IBP5 has recently been deemed a molecular biomarker
for predicting response to therapy and clinical outcome in patients with different cancers [17]. Also,
it has been implicated as a cancer promoter or cancer repressor in various tumor types to regulate
migration, differentiation, cell attachment, and cell morphology [38,39]. Although there is less evidence
for the role of IBP7 in cancer, some groups have reported that IBP7 can promote cancer progression.
In non-small cell lung carcinoma, IBP7 was associated with metastatic disease [40]. In T-cell acute
lymphoblastic leukemia, IBP7 inhibited proliferation by causing G0/G1 arrest and induced drug
resistance [41]. In gastric cancer, IBP7 overexpression was associated with tumor progression and poor
survival [42].
PDGFD has recently gained tremendous amount of attention due to its involvement in
carcinogenesis. In agreement with the oncogenic function of PDGFD in human malignancies, PDGFD
overexpression has been detected in a variety of cancers including prostate, lung, renal, ovarian, brain,
and pancreatic cancer [18,43]. PDGFD regulates multitude cellular pathways including PI3K/Akt,
NF-κB, Notch, ERK, mTOR, MAPK, VEGF, MMPs, Cyclin D1 and BCL2 [44–49]. Moreover, PDGFD
has been found to regulate the EMT process that is important for tumor metastasis [44,45,50,51].
Prostate cancer cells with an EMT phenotype induced by PDGFD displayed CSC features, including
increased expression of SOX2, NANOG, OCT4, and Notch-1, and enhanced sphere-forming ability
and rapid tumor growth in vivo [44]. In addition, it has also been reported that tissue-resident stem
cells induce EMT through interaction with the TME via PDGFD, thereby leading to increased number
of CSCs and tumor growth [50].
Since FBLN3, IBP5, IBP7, and PDGFD play oncogenic roles through the regulation of tumor cell
growth, invasion, metastasis, EMT, and CSCs, targeting these proteins, their receptors, or downstream
signaling pathways could be valuable strategies to interfere with stromal-cancer cell heterotypic
communication. Interestingly, we found that pharmacologic inhibition of EGFR, IGFR, and PDGFR
signaling pathways efficiently blocked CAF-induced orosphere formation and anchorage-independent
growth in HNSCC cells. Nevertheless, it is plausible that the potent anti-stemness effects observed
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by targeting EGFR, IGFR, and PDGFR pathways could also be due to a direct effect on the tumor
cells, since these signaling pathways are frequently altered in different cancers, including HNSCC.
A limitation of this study is that only one population of primary CAFs and NFs were used.
4. Materials and Methods
4.1. Drugs
EC-8042 (EntreChem, Oviedo, Spain), OSI-906 (Selleckchem, Suffolk, UK), CP-673451 (Selleckchem,
Suffolk, UK), 2-Guanidinoethylmercaptosuccinic acid (GEMSA) (Abcam, Cambridge, UK), and
Gefitinib (TOCRIS Bioscience, Bristol, UK) were prepared as 1 mM solutions in sterile DMSO or
water, according to manufacturer’s indications, for in vitro experiments, maintained at −20 ◦C and
brought to the final concentration just before use.
4.2. Cell Culture
FaDu cells were purchased to the American Type Culture Collection, and the HNSCC cell line
SCC38 derived from a primary tumor (T2N0M0) was kindly provided by Dr. R. Grenman (Department
of Otolaryngology, University Central Hospital, Turku, Finland) [52]. Primary cancer-associated
fibroblasts (CAFs) were obtained from minced tumor tissue of surgically resected HNSCC at the
Hospital Universitario Central de Asturias. Normal dermal fibroblasts (NF) were obtained from the
dermis of human neonatal foreskin, by enzymatic cell disaggregation as described [53]. Cell line
authentication was performed by DNA (STR) profiling at the SCT Core Facilities (University of Oviedo,
Asturias, Spain). All cell lines were tested periodically for mycoplasma contamination by PCR to
specifically amplify a conserved region of the mycoplasma 16S ribosomal RNA gene (Biotools Detection
kit, Madrid, Spain).
HNSCC cells and fibroblasts were grown in DMEM (Biowest, Nuaillé, France) supplemented
with 10% fetal bovine serum (FBS) (Gibco, Waltham, MA, USA), 100 U/mL penicillin (Biowest,
Nuaillé, France), 200 mg/mL streptomycin (Biowest, Nuaillé, France), 2 mM L-glutamine, 20 mM
HEPES (pH 7.3) (Biowest, Nuaillé, France), and 100 mM MEM non-essential amino acids (Biowest,
Nuaillé, France).
4.3. Conditioned Media Production
Primary CAFs and NFs were grown in T175 flask (Corning, Corning, NY, USA) with complete
medium until reaching 80–90% confluence (approx 4–5×106 cells). Then, medium was replaced
and cells were grown for 72 h in 20 mL of DMEM-F12 (GE Healthcare, Pittsburg, PA, USA) with
100 U/mL penicillin (Biowest, Nuaillé, France), 200 mg/mL streptomycin (Biowest, Nuaillé, France)
in the absence of supplements or FBS and also without phenol red (for Mass Spec analysis). Next,
conditioned media (CM) were collected and filtered through a 0.45 µm pore filter (Sigma-Aldrich,
St. Louis, MO, USA) and frozen at −80 ◦C until use.
4.4. Anchorage-Independent Cell Growth
For anchorage-independent cell growth, normal 96-well tissue culture plates (Corning) were
coated with 10 g/L of the anti-adhesive polymer poly-2-hydroxyethyl methacrylate (polyHEMA,
Sigma-Aldrich) in 95% ethanol and dried at 56 ◦C for 16 h to prevent cell attachment.
PolyHEMA-coated plates were sterilized with UV-light for 30 min before use.
FaDu and SCC38 cells were plated into 96-well tissue culture plates at a density of 10,000 cells
per well. Cell proliferation was measured after 4 days. Quantification of cell number was determined
in quadruplicates using a tetrazolium-based MTS test (CellTiter 96 Aqueous One Solution Cell
Proliferation Assay from Promega, Madison, WI, USA), reading the absorbance at 490 nm with
the use of a Synergy HT plate reader (BioTek, Winooski, VT, USA).
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4.5. Orosphere Formation Assay
HNSCC-derived cells lines were plated at a density of 500 cells/mL in 75-cm2 flask (5000 cells) or
6-well tissue culture plates (1000 cells/well), treated with a sterile solution of polyHEMA (10 g/L in 95%
ethanol) (Sigma-Aldrich) to prevent cell attachment, and grown in either DMEM-F12 (GE Healthcare,
Pittsburgh, PA, USA) without any supplements, conditioned media from CAFs or NFs, or the
standard cancer stem cell medium [54,55], which is composed of DMEM-F12 supplemented with 1%
Glutamax (Life Technologies, Waltham, MA, USA), 2% B27 Supplement (Life Technologies, Waltham,
MA, USA), 20 ng/mL human EGF (PeproTech, London, UK), 10 ng/mL human bFGF (PeproTech,
London, UK), 4 µg/mL insulin (Sigma-Aldrich), 100 U/mL penicillin, and 200 mg/mL streptomycin.
The above medium will be referred to in this manuscript as supplemented medium as opposed to
non-supplemented DMEM-F12 medium.
After 10–12 days, well-formed spheres were photographed in Leica Microsystems microscope
DMIL T, coupled with a Leica DC500 High-resolution Digital Camera (Leica Microsystems, Barcelona,
Spain). Then the spheres were centrifuged at 500 rpm for 5 min, washed with PBS and collected for
RNA extraction or MTS assay.
4.6. RNA Extraction and Real-Time RT-PCR
Total RNA was extracted from HNSCC cells using Trizol reagent (Invitrogen Life Technologies,
Waltham, MA, USA), and cDNA synthesized with Superscript II RT-PCR System (Invitrogen Life
Technologies), according to manufacturer’s protocols. Gene expression was analyzed by Real-time
PCR using the StepOnePlus Real-Time PCR System (Applied Biosystems, Waltham, MA, USA)
following Applied Biosystems’ SYBR Green Master Mix protocol. Reactions were carried out using the
primers detailed in Table S1. The constitutively expressed RPL19 ribosomal coding gene was used as
endogenous control. The relative mRNA expression was calculated using the 2−∆∆CT method.
4.7. Secretome Analysis by Mass Spectrometry
Conditioned media from NFs and CAFs were obtained as above described, and protein
concentration was determined by Pierce BCA Protein Assay Kit (Thermo Fisher, Waltham, MA,
USA). Three independent batches of CM were produced from each experimental condition and used
as biological replicates.
50 µg of protein (for each CM) were digested overnight with immobilized TLCK-trypsin (20 TAME
units/mg) (Thermo Scientific, Waltham, MA, USA) for 16 h at 37 ◦C. The resultant peptide solutions
were desalted by solid phase extraction (SPE) using Oasis HLB extraction cartridges (Waters UK Ltd.,
Manchester, UK) according to manufacturer’s instructions. Briefly, cartridges coupled to a vacuum
manifold set at 5 mm Hg, were activated with 1 mL of 100% acetonitrile (ACN) and equilibrated with
1.5 mL of wash solution (1% ACN, 0.1% TFA in water). After the cartridges were loaded with peptide
solution, they were washed with 1 mL of wash solution. Peptides were eluted with 0.5 mL of 50%
ACN containing 0.1% TFA and dried in a speed vacuum centrifuge.
Peptide pellets were solubilized in 0.1% TFA and run in two mass spectrometry platforms
consisting in an LTQ-Orbitrap XL (Thermo Scientific, Waltham, MA, USA) coupled to a nanoACQUITY
ultra performance LC (Waters Corp., Milford, MA, USA) and a QExactive plus (Thermo Scientific)
online connected to a Ultimate 3000 RSLC chromatographer (Thermo Scientific). For the LTQ-Orbitrap
XL system, peptides were loaded into a nanoACQUITY trap column and separated on BEH C18 nano
ACQUITY column. Separation was performed using a 180-min gradient with solvent B 5–25% at a
flow rate of 300 nL/min (mobile phase B; 100% ACN and 0.1% FA; mobile phase A; 100% water and
0.1% FA). The mass spectrometer was operated in data-dependent acquisition mode for top 5 CID
acquisitions. For the QExactive plus system, peptides were loaded into an Acclaim PepMap 100 trap
column and separated on an Acclaim PepMap RSLC analytical column. Separation was performed
using a 120-min gradient with solvent B 5–25% at a flow rate of 300 nL/min (mobile phase B; 100%
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ACN and 0.1% FA; mobile phase A; 100% water and 0.1% FA). The mass spectrometer was operated in
data-dependent acquisition mode for top 15 CID acquisitions.
4.8. Mass Spectrometry Data Analysis
Raw files were converted to peak lists (in the Mascot Generic Format) using Mascot Distiller
(version 2.3.0) and searched using Mascot Server (version 2.3.01) against the SwissProt Uniprot
database (2012-03-10) restricted to the relevant taxonomy. Mass windows for tolerance for MS scans
were 10 ppm and 600 mmu for MS/MS. Fixed modification of carbamidomethylation of cysteine and
variable modifications of oxidation of methionine and glutamine to pyroglutamate conversion were
permitted. Mascot result files were parsed using a Perl script that uses the Mascot Parser files provided
by Matrix Science. The threshold for accepting peptides as being positively identified was set at an
expectancy score of 0.05.
For individual peptide quantification, we used Pescal, a software that automates the construction
of extracted ion chromatograms for all peptides identified across all samples being compared [56,57].
Independent Pescal analyses were run for the quantification of peptides identified in the LTQ-Orbitrap
XL or QExactive systems. Protein intensity calculation was automated with an in house developed
script that sums the signals of peptides obtained from both platforms and comprised in the same
protein. Data were normalized by dividing each protein intensity by the sum of all protein intensities
within a sample. Fold changes were calculated by averaging the normalized intensities of peptides
within a sample group and dividing these by the intensities of the control group. Fold changes were
then log transformed before calculation of significance using an unpaired t-test.
4.9. Statistical Analysis
The data are presented as the mean ± standard deviation (SD), unless otherwise stated, and
compared using unpaired Student’s t-test or one-way ANOVA test and Holm-Sidak’s multiple
comparisons test. The normality of the data was analyzed using the Kolmogorov-Smirnov test.
Statistical analysis was performed using GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla,
CA, USA). p values less than 0.05 were considered statistically significant (* p < 0.05; ** p < 0.01;
*** p < 0.005).
5. Conclusions
Together our findings uncover novel insights into the tumor stroma–CSC communication, and
provide also a novel therapeutic rationale to effectively block the CAF-enhanced CSC niche signaling
circuit, to ultimately overcome CSC-mediated disease progression and resistance to therapy.
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Abbreviations
CAFs Cancer-associated fibroblasts
CSC Cancer stem cells
HNSCC Head and neck squamous cell carcinomas
EMT Epithelial-mesenchymal transition
NFs Normal fibroblasts
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
IGF Insulin-like growth factor
IGFR Insulin-like growth factor receptor
PDGF Platelet-derived growth factor
PDGFR Platelet-derived growth factor receptor
ECM Extracellular matrix
TME Tumor microenvironment
MMPs Matrix metalloproteinases
MS Mass spectrometry
GEMSA 2-Guanidinoethylmercaptosuccinic acid
FBS Fetal bovine serum
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
CM Conditioned media
polyHEMA poly-2-hydroxyethyl methacrylate
FGF Fibroblast growth factor
SPE Solid phase extraction
CAN Acetonitrile
TFA Trifluoroacetic acid
FA Formic acid
CBPE Carboxypeptidase E
PDGFD Platelet-derived growth factor D
FBLN3
EGF-containing fibulin-like extracellular matrix
protein-1
IBPs Insulin-like growth factor binding protein
IBP5 Insulin-like growth factor binding protein-5
IBP7 Insulin-like growth factor binding protein-7
HGF Hepatocyte growth factor
IL-6 Interleukin-6
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